Home

Numerous reports in the media and professional medical literature have expressed grave concerns about the effectiveness of currently available antibiotics against multi-drug resistant bacteria. Some strains of pathogenic bacteria have demonstrated rapidly evolving defense strategies that render antibiotics worthless. One defense strategy used by microbes is to secrete a substance known as biofilm, which provides a protective shield effectively blocking antimicrobials from contacting the microbe.

An innovative technology, based upon research conducted by the Emerging Disease Research Group at the University Of Georgia, has been developed that significantly enhances and potentiates the killing activity of topical antimicrobials. This new class of antimicrobials destroys protective biofilms as well as the integrity and functionality of the microbe’s cellular membrane. In vitro testing has shown that microbes that quickly develop resistance to antimicrobials in vivo, are unlikely to remain resistant or develop resistance to PotentiatedTM antimicrobials.

“We started with the goal of stopping multi-drug resistant bacteria. Physicians now have a new weapon in their antimicrobial arsenal to fight even the most dangerous bacteria, like the infection that affected Christopher Reeve,” said Branson Ritchie PhD, Distinguished Research Professor at the University of Georgia.

SilvionTM and SilvaKlensTM are the fist two products incorporating this revolutionary PotentiatedTM antimicrobial technology to receive FDA clearance for professional use.

Clinical Cases, SilvionTM, SilvaKlenzTM,

Broad Spectrum antimicrobial coverage even against drug resistant microbes such as Methicillin resistant Staphylococcus aureus (MRSA), Vancomycin resistant Enteroccus faecalis (VRE), multi-drug resistant Pseudomonas aeruginosa, and multi-drug resistant Acinetobacter baumannii (Iraqi)

1st and 2nd Degree Burns Stage I-IV Pressure Ulcers, Venous Stasis Ulcers

Diabetic Ulcers, Dermal Lesions, Skin Irritation, Abrasions

“A bacterium is likely to lose its resistance to an antibiotic when our potentiation technology is added to the drug,” explains Ritchie. “Preliminary findings also show that the potentiated antimicrobials reduce pain, heal wounds more rapidly, and break through bacterial biofilms.”

Molecular Therapeutics, Silvion, SilvaKlenz, Potentiator and Potentiated are registered trademarks

Molecular Therapeutics, LLC 425 River Road, Suite 422 Athens, GA 30602 Contact Us